以岭药业创新药进入国家医保 董事长吴相君详解守正创新路径

Core Viewpoint - The 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog was released, highlighting the importance of innovative drugs in reducing public burden and promoting high-quality development in the pharmaceutical industry [1][3]. Group 1: Policy and Industry Impact - The adjustment mechanism of the national medical insurance catalog is becoming more scientific and standardized, facilitating the rapid entry of innovative drugs into clinical use [3]. - The support for innovative drugs with high clinical value and significant patient benefits aligns with the government's focus on people-centered development [3][4]. Group 2: Company Innovations and Achievements - Yiling Pharmaceutical has established over 60 standardized Chinese medicinal herb cultivation bases to ensure quality from the source and has developed a comprehensive quality traceability system [4]. - The company has conducted over 40 evidence-based medical studies, with significant contributions to the field of traditional Chinese medicine, including four entries in the top ten medical research projects in 2024 [4]. Group 3: New Drug Approval - Yiling Pharmaceutical's Qifang Bitong Pian, a treatment for allergic rhinitis, has been approved for inclusion in the 2025 national medical insurance catalog, marking the company's fifth innovative traditional Chinese medicine to pass national negotiations [5][6]. - This drug is recognized as a Class 1.1 new drug and fills a clinical gap in the treatment of persistent allergic rhinitis [5].